Shang‐Hung Chen

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells

Tzu‐Yu Lin, Hsiu-Han Chan, Shang‐Hung Chen et al. · Autophagy · 2019 · 148 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells

Jane Ying-Chieh Lee, Ching-Wen Kuo, Shing-Ling Tsai et al. · Frontiers in Pharmacology · 2016 · 64 citations · Full text

Life Sciences, Oncology, Pharmacology +17

SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential

Yu-Feng Tian, Tzu-Ju Chen, Ching-Yih Lin et al. · Tumor Biology · 2013 · 44 citations

Medicine, Oncology, Pharmacology +17

HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells

Wen-Tsung Huang, Yu‐Hsuan Tsai, Shang‐Hung Chen et al. · Frontiers in Pharmacology · 2017 · 35 citations · Full text

Medicine, Molecular Biology, Oncology +17